NeuroSense Therapeutics (NRSN) Interest Coverage Ratio (2021 - 2024)
NeuroSense Therapeutics (NRSN) posted Interest Coverage Ratio of 0.25 for Q4 2024, up 78.45% sequentially from 1.15 in Q4 2023, and up 78.45% YoY from 0.14 in Q1 2024.
NeuroSense Therapeutics (NRSN) Interest Coverage Ratio (2021 - 2024) Analysis & Trends
NeuroSense Therapeutics has reported Interest Coverage Ratio for 4 years, with the latest figure at 0.25 in Q4 2024.
- Quarterly Interest Coverage Ratio rose 78.45% year-over-year to 0.25 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 1.39 (up 94.84% YoY) and the FY2025 annual result came in at 1.09, up 21.31% from the prior year.
- Interest Coverage Ratio grew to 0.25 in Q4 2024 per NRSN's latest filing, from 1.15 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 331.9 in Q3 2022 and troughed at 79.25 in Q2 2021.
- A 4-year average of 66.2 and a median of 4.76 in 2021 frame the typical range for Interest Coverage Ratio.
- The widest YoY moves for Interest Coverage Ratio: up 229.43% in 2022, down 154.44% in 2022.
- Over 4 years, Interest Coverage Ratio stood at 4.76 in 2021, then plunged by 154.44% to 2.59 in 2022, then jumped by 55.52% to 1.15 in 2023, then soared by 78.45% to 0.25 in 2024.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 0.25, 1.15, and 218.83 for Q4 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -0.25 |
| Dec 31, 2023 | -1.15 |
| Sep 30, 2023 | 218.83 |
| Jun 30, 2023 | 1.79 |
| Mar 31, 2023 | 9.65 |
| Dec 31, 2022 | -2.59 |
| Sep 30, 2022 | 331.90 |
| Jun 30, 2022 | 102.57 |
| Mar 31, 2022 | 141.91 |
| Dec 31, 2021 | 4.76 |
| Jun 30, 2021 | -79.25 |